Third, patients with T2D receiving treatment of sodium–glucose cotransporter 2 inhibitor or glucagon-like peptide-1 receptor agonist may have reduced cardiovascular mortality in clinical trials. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.